Does Anemia Have a Potential Effect on Type 2 Hepatorenal Syndrome?
Table 3
Clinical and biological features of patients.
Type 2 HRS
HRS
Age (median years)
68.33 ± 10.93
61.65 ± 11.9
0.129
Gender (M/F)
7/2
20/21
0.114
Ascites (present/total)
9/9
18/41
0.002
Encephalopathy
5
3
<0.001
Hemoglobin (g/dL)
7.62 ± 2.45
10.82 ± 2.25
<0.001
Platelet (×103/μl)
147.88 ± 65.86
119.17 ± 64.14
0.232
Hematocrit (%)
29.22 ± 6.43
34.48 ± 7.12
0.047
Creatinine (μmol/l)
259.11 ± 151
73.65 ± 29.71
0.003
Total bilirubin
87.11 ± 55.9
31.31 ± 34.34
<0.001
Albumin (g/dL)
28.11 ± 2.42
32.77 ± 2.73
<0.001
INR
1.64 ± 0.32
1.28 ± 0.22
<0.001
CTP score
9.77 ± 1.3
6.95 ± 2.22
0.001
MELD score
22.77 ± 4.43
11.5 ± 4.67
<0.001
HRS, hepatorenal syndrome; M, male; F, female; INR, international normalized ratio; CTP, Child–Turcotte–Pugh; MELD, model of end-stage liver disease. .
